Loss-of-function mutations of microRNA-142-3p promote ASH1L expression to induce immune evasion and hepatocellular carcinoma progression

Figure 1 ASH1L protein expression levels in patient tissues. A: Representative images showing ASH1L expression in normal liver and hepatocellular carcinoma tissues from the same patient; B and C: Representative images illustrating weak expression of ASH1L in the tumor low expression group and strong expression of ASH1L in the tumor high expression group; D: ASH1L expression in patients’ tissues analyzed by western blot; E: A quantitative analysis of the western blot data provided a numerical representation of ASH1L expression levels in the tumor and normal tissues; F: Quantitative results of ASH1L expression among patients’ tissues obtained by quantitative real-time polymerase chain reaction. ^cP < 0.001. ^dP < 0.0001. T: Tumor tissues; N: Liver tissues; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase.